Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MDXG Stock Forecast 2025-2026
$6.93
Current Price
$1.03B
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MDXG Price Targets
+87.6%
To High Target of $13.00
+73.2%
To Median Target of $12.00
+73.2%
To Low Target of $12.00
MDXG Price Momentum
+0.7%
1 Week Change
-6.9%
1 Month Change
-28.4%
1 Year Change
-28.0%
Year-to-Date Change
-31.7%
From 52W High of $10.14
+19.7%
From 52W Low of $5.79
📊 TOP ANALYST CALLS
Did MDXG Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MiMedx is one of their latest high-conviction picks.
Latest MDXG Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, MDXG has a bullish consensus with a median price target of $12.00 (ranging from $12.00 to $13.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $6.93, the median forecast implies a 73.2% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ross Osborn at Cantor Fitzgerald, projecting a 87.6% upside. Conversely, the most conservative target is provided by Ross Osborn at Cantor Fitzgerald, suggesting a 73.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDXG Analyst Ratings
5
Buy
0
Hold
0
Sell
MDXG Price Target Range
Low
$12.00
Average
$12.00
High
$13.00
Current: $6.93
Latest MDXG Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDXG.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 31, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $12.00 |
| Jul 15, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $11.00 |
| Feb 27, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $13.00 |
| Aug 1, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $12.00 |
| Aug 1, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $11.00 |
| Jul 2, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Initiates | $11.00 |
| May 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $11.00 |
| Mar 7, 2024 | Lake Street | Brooks O'Neil | Buy | Initiates | $12.00 |
| Mar 1, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $14.00 |
| Oct 31, 2023 | Mizuho | Anthony Petrone | Buy | Maintains | $12.00 |
| Oct 27, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $12.00 |
| Aug 2, 2023 | Mizuho | Anthony Petrone | Buy | Maintains | $12.00 |
| Aug 2, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $11.00 |
| Jun 21, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.00 |
| May 3, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $9.50 |
| Mar 2, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $8.00 |
| Oct 13, 2022 | Mizuho | Anthony Petrone | Buy | Initiates | $7.00 |
| Sep 7, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.00 |
| Sep 14, 2021 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.50 |
| Jul 26, 2021 | Northland Capital Markets | Outperform | Initiates | $N/A |
MiMedx Group, Inc. (MDXG) Competitors
The following stocks are similar to MiMedx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MiMedx Group, Inc. (MDXG) Financial Data
MiMedx Group, Inc. has a market capitalization of $1.03B with a P/E ratio of 25.7x. The company generates $393.44M in trailing twelve-month revenue with a 10.4% profit margin.
Revenue growth is +35.3% quarter-over-quarter, while maintaining an operating margin of +19.5% and return on equity of +19.4%.
Valuation Metrics
Market Cap
$1.03B
Enterprise Value
$902.48M
P/E Ratio
25.7x
PEG Ratio
0.2x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+35.3%
Gross Margin
+83.5%
Operating Margin
+19.5%
Net Margin
+10.4%
EPS Growth
+106.9%
Financial Health
Cash/Price Ratio
+13.8%
Current Ratio
4.4x
Debt/Equity
7.6x
ROE
+19.4%
ROA
+12.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MiMedx Group, Inc. (MDXG) Business Model
About MiMedx Group, Inc.
What They Do
Develops regenerative medicine bioimplants from placental tissue.
Business Model
MiMedx generates revenue through the development and commercialization of bioimplants that leverage human placental tissues to aid in healing various medical conditions. Their products serve healthcare providers in wound care, ophthalmology, and orthopedics, addressing critical needs in the treatment of chronic wounds and injuries.
Additional Information
The company emphasizes research and development in tissue engineering, which enhances its position in the biopharmaceutical market. By focusing on innovative solutions, MiMedx aims to improve patient outcomes and lower treatment costs, making it a significant player in advancing regenerative medicine technologies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
837
CEO
Mr. Joseph H. Capper
Country
United States
IPO Year
2008
Website
www.mimedx.comMiMedx Group, Inc. (MDXG) Latest News & Analysis
Latest News
Quick Summary
MiMedx Group, Inc (MDXG) has reached a key support level, with its 50-day moving average crossing above the 200-day moving average, indicating a potential bullish trend.
Why It Matters
MiMedx's "golden cross" indicates bullish momentum, suggesting potential for price increases. The key support level may attract more buyers, impacting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Interim results and a recent industry presentation show that EPIEFFECT provides clinical benefits over standard of care (SOC).
Why It Matters
Positive interim results and clinical benefits of EPIEFFECT over standard care may boost investor confidence, indicating potential for increased market share and revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MiMedx Group, Inc. will participate in the Craig-Hallum Alpha Select Conference on Nov 18 and the Canaccord MedTech Forum on Nov 20, offering 1:1 sessions with senior management.
Why It Matters
Participation in investor conferences signals MiMedx's commitment to transparency and engagement, potentially influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MiMedx Group, Inc. (Nasdaq: MDXG) commented on the CMS release of the CY 2026 Physician Fee Schedule final rule, published on November 3, 2025.
Why It Matters
The CMS release of the CY 2026 Physician Fee Schedule could impact MiMedx's revenue and reimbursement rates, influencing its financial performance and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
MiMedx: Breakout Setup Into A Policy Overhaul
1 month ago
Quick Summary
MiMedx Group reported record Q3 revenue and strong earnings, with growth in its Surgical segment. It is managing reimbursement risks and is considered undervalued by ~20%.
Why It Matters
MiMedx Group shows strong growth potential with record revenue and proactive risk management. Its undervaluation suggests a buying opportunity, supported by solid financial performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Wall Street Analysts Predict a 64.86% Upside in MiMedx (MDXG): Here's What You Should Know
1 month ago
Quick Summary
Analysts' price targets for MiMedx (MDXG) suggest a potential 64.9% upside, supported by a consensus increase in earnings estimates.
Why It Matters
Analysts' bullish price targets suggest significant upside potential for MiMedx (MDXG), indicating positive sentiment and possible stock appreciation driven by increased earnings estimates.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About MDXG Stock
What is MiMedx Group, Inc.'s (MDXG) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, MiMedx Group, Inc. (MDXG) has a median price target of $12.00. The highest price target is $13.00 and the lowest is $12.00.
Is MDXG stock a good investment in 2026?
According to current analyst ratings, MDXG has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.93. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDXG stock?
Wall Street analysts predict MDXG stock could reach $12.00 in the next 12 months. This represents a 73.2% increase from the current price of $6.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MiMedx Group, Inc.'s business model?
MiMedx generates revenue through the development and commercialization of bioimplants that leverage human placental tissues to aid in healing various medical conditions. Their products serve healthcare providers in wound care, ophthalmology, and orthopedics, addressing critical needs in the treatment of chronic wounds and injuries.
What is the highest forecasted price for MDXG MiMedx Group, Inc.?
The highest price target for MDXG is $13.00 from Ross Osborn at Cantor Fitzgerald, which represents a 87.6% increase from the current price of $6.93.
What is the lowest forecasted price for MDXG MiMedx Group, Inc.?
The lowest price target for MDXG is $12.00 from Ross Osborn at Cantor Fitzgerald, which represents a 73.2% increase from the current price of $6.93.
What is the overall MDXG consensus from analysts for MiMedx Group, Inc.?
The overall analyst consensus for MDXG is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are MDXG stock price projections?
Stock price projections, including those for MiMedx Group, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 10:21 AM UTC